ElectroMedical Technologies Inc (ID) (EMED)

Timeline for possible news as projected by AI.

Expected Window for the News and Roll-Up Completion

The Longevity Summit Catalyst

Howard Leonhardt is confirmed to present at the Longevity Summit Dublin from June 24th to June 26th, 2026. In biotech and longevity ventures, international summits serve as premier launchpads to pitch institutional investors, source capital, and build "roadshow" momentum. Utilizing the global media presence at Trinity College Dublin to announce a definitive roll-up agreement allows Lionheart to maximize public momentum, generate institutional interest, and kick off the official roadshow for their $250M+ IPO.

Will news break before the summit? The corporate actions or initial frameworks will likely be announced or finalized 1 to 2 weeks before the summit. Presenting a complete, aggregated ecosystem (including the physical manufacturing footprint of EMED) makes for a significantly stronger pitch to the international venture capitalists and institutional investors in attendance.

Will news break during the summit? Expect operational or vision-based press releases during the presentation windows. If the structural deal isn't fully signed by mid-June, Howard Leonhardt will likely use his presentation slot to formally detail the launch of the broader "Lionheart Health Roll-Up Ecosystem" and define EMED's exact operational role within it.

-------------------------------------------------------------------------------------

Because Lionheart Health's core mission is to reverse aging by 10+ years through regenerative and bioelectric stimulation (the exact tech powering EMED's WellnessPro line), this summit is the ideal platform to showcase the unified entity. Corporate announcements or joint venture updates are frequently synchronized with these presentations to maximize visibility.

---Why the Summit Matters: Howard Leonhardt frequently uses high-profile, science-led conferences to showcase technology updates and announce corporate milestones. Presenting at Trinity College Dublin gives him a global stage of investors, clinicians, and biotech partners.

---Expected Timeline: You can logically expect a press release or definitive roll-up agreement announcement immediately before or during the summit (June 22–26, 2026) to maximize market buzz and build momentum for the upcoming IPO.

------------------------------------------------------------------------------------

The SEC S-1 Public Filing Window (Late June – July 2026)
If Lionheart follows standard confidential IPO mechanics under the JOBS Act, they must eventually move their confidential regulatory drafts into a public SEC S-1 filing.

The S-1 Alignment: With Lionheart targeting a 2026 Initial Public Offering (IPO), any pre-IPO restructuring must wrap up sequentially. If a roll-up announcement does not break directly during the Dublin event, subsequent public disclosures should follow when Lionheart files its visible Form S-1 registration statement

The corporate timeline, financial maneuvering, and Howard Leonhardt’s public presentation window point to late June through mid-July 2026 as the primary window for the completion of the roll-up and subsequent strategic announcements

---The 15-Day Rule: Lionheart must make its confidential S-1 public on EDGAR at least 15 days before launching an official investor roadshow.

---What to expect: Once the S-1 goes public, the "dark period" ends. The full structural details, equity conversion ratios for EMED shareholders, and the formal debt-forgiveness or buyout terms will become fully transparent.

OTCID Today, emerged from pink limited

Revenge for what?Not only am I still holding my (many) shares, I am bullish. I guess we’ll see how it ends up! As Tom Petty said, the waiting is the hardest part. (Alongside managing the low-level anxiety about possibly regretting not getting .0001 for one’s shares if this does somehow go to nothing.) I hold out hope for a great outcome. Good luck to us all!

I guess Wolfman is believing he got his revenge
For what it is worth I still have my shares. Not selling! If this becomes a class action suit then I am up for it!

I guess Wolfman is believing he got his revenge
For what it is worth I still have my shares. Not selling! If this becomes a class action suit then I am up for it!

Ahh, the classic paradox – “fountain-side” syndrome!! I would respond to the great poet by saying “It’s all in your frame of mind. Rather than focusing on frustration, it is sometimes better to fully recognize the broader opportunities in front of you.” That’s my philosophical and investment take on it!! 😀

As the great French poet François Villon (trans. Richard Wilbur) wrote, “I die of thirst, here at the fountain side.”

Leonhardt Ventures LLC Surpasses Historic Milestone with Over 1 Million Patients Treated with Its Inventions and Technology Platforms
HUNTINGTON BEACH, Calif., May 23, 2026

Leonhardt Ventures LLC announced today that technologies, inventions, and derivative product families associated with founder Howard J. Leonhardt and affiliated innovation programs have now contributed to the treatment of more than one million patients worldwide.

The milestone reflects over four decades of innovation spanning cardiovascular devices, regenerative medicine, bioelectric stimulation, intravascular lung, radiation catheters, structural heart technologies, catheter systems, stent grafts, percutaneous heart valves, and biologics therapies.

This seems positive to me. It seems there’s at least a theoretical scenario where the toxic lenders have to capitulate, or negotiate terms. Where they essentially don’t hold all the cards. What’s crucial in what AI has generated here is that it seems to think *we common shareholders* wouldn’t get wiped out, in any scenario. At worst, the AS count would jump up to something like 7B to accommodate the newly created shares if the noteholders don’t accept a renegotiation, and we’d have a proportional share of, let’s say at very worst, a $5M buyout. The math on that would still yield a share price of .0007 in a cash deal, or its virtual equivalent in Lionheart IPO stock. That’s not perhaps what we’ve hoped for, but it’s still better than .0002, and more importantly, it’s better than an imagined scenario where we get nothing if Lionheart forecloses. Also, it’s a worst-case scenario. Maybe Lionheart settles the 514k; maybe the AS count stays at 5B. And maybe they pay more than 5M for the company. If any of those contingencies emerge, then the share price creeps up from .0007. I’m feeling decently positive about our chances. Thanks for running these scenarios, Win. Good luck to us all!

Lionheart will have an exhibit booth at The Longevity Show in London June 26 & 27, 2026.

The Lionheart 240 Stimulus™ is pictured in the ad.

TeacherMan, these scenarios per A.I. make sense to me. Any comments?

The corporate maneuvering between Electromedical Technologies (EMED) and Lionheart Health is a classic example of micro-cap restructuring and distress mechanics ahead of a planned Initial Public Offering (IPO).

Why Lionheart Loaned the $500,000
Lionheart likely issued the $500,000 loan to bridge a cash-flow gap while maintaining strict operational leverage over EMED.

Bridging Production Delays: EMED faced public challenges with manufacturing and component delays. The $500,000 loan was likely working capital needed to physically fulfill Lionheart's own $473,000 pre-order of the WellnessPro Infinity system placed in August 2024.

Collateral Strategy: By structuring the cash infusion as a fully secured loan (rather than adding to the pre-order balance), Lionheart ensured its cash was backstopped by all of EMED’s physical assets, patents, and intellectual property.


Why EMED Voluntarily Defaulted on April 1, 2026

It is highly probable that EMED's default on the April 1, 2026 deadline was a coordinated action—or a concession—rather than an accidental oversight. In micro-cap roll-ups, an engineered default serves specific strategic purposes:

Wiping Out and Squeezing Toxic Noteholders

EMED's Q1 2026 report indicates $514,000 in separate noteholder debt. Convertible notes in the OTC markets frequently feature predatory, "toxic" dilution terms where lenders convert debt into billions of cheap shares. By triggering a default on a senior, fully secured loan, Lionheart places its claim at the front of the line. The minor noteholders now face total wipeout if foreclosure occurs, forcing them to either sell their notes at a steep discount or agree to unfavorable settlement terms.

Artificially Depressing the Valuation for a Cheap Buyout

Lionheart wants a roll-up acquisition before its IPO. If EMED has stellar financials, Lionheart must pay a premium to absorb them. By allowing EMED to showcase "poor financials" and a distressed balance sheet, the buyout valuation remains low. This prevents Lionheart from overpaying and avoids diluting its own future IPO equity.


Explaining the High Volume and Wiped-Out Bid

A high-volume trading session where the bid is entirely wiped out (driving the price down to its absolute floor, such as $0.0001) is typically caused by three distinct pressures:

Dilution from Convertible Notes: Pre-existing noteholders, seeing the looming foreclosure risk, may be frantically converting their notes into common shares and dumping them "at market" to claw back any capital before a complete wipeout occurs.

Institutional / Insider Accumulation: Lionheart affiliates or coordinated market makers may be forcing the bid down to accumulate massive blocks of floating shares at rock-bottom prices. This allows them to secure voting control or clear out the public float cheaply.

Retail Panic: Retail investors reading the "going concern" language and foreclosure risk in the Q1 report are capitulating and selling into whatever thin bids remain.


Future Scenarios and Outcomes for EMED Shareholders

The Debt-to-Equity

Strategic Mechanics: Lionheart offers to forgive the $550,000 balance (principal + penalty) and settles the $514k noteholder debt in exchange for direct equity control of EMED. They merge EMED into Lionheart.

What it Means for Common Shareholders: Moderate/Positive Up-side. Shareholders are converted into private or IPO-bound Lionheart shares at a set conversion ratio.


Clean Cash Buyout

Strategic Mechanics: Lionheart completes its public S-1 filing, raises capital, and buys out EMED entirely for a nominal lump sum (e.g., $10M–$25M), using a portion to clear the noteholders.

What it Means for Common Shareholders: Fixed Cash Payout. Shareholders receive a fixed, per-share cash distribution based on the total purchase price.

Thanks again. I do see both lines on the Q1 report—the 514k and the 500k. So, that means the convertible debt isn’t paid off. I guess we’ll see what’s coming. It wasn’t pleasant to see the bid get wiped out today. My hope is that it was impatient retail (totally understandable) and not an insider dumping, or else dilution. I’ve watched the OS count carefully every day; it hasn’t changed from the 3.73B number in months. One would think they would be required to update the number if it changes. I’ve been holding and hoping that this will work out for us. It leaves one with a queasy feeling to know one could have dumped into the bid and recouped a lot of one’s investment, and now the bid is gone. I have a hefty number of shares. I say that not as a boast but as an indicator of how stressful it’s been trying to decide what to do with them. I’ve held through it all. I hope it will prove to have been the right call. I hope for all of us that this pays off. One thing I can say is that if Lionheart IPOs successfully and profitably, and Wolfson is standing astride him, and the former EMED tech is gleaming as a jewel in the new company’s diadem, but we former shareholders are left with nothing after some accounting gamesmanship has spirited away the value of our shares, it will not feel good, to say the least. I would hope we would get some form of Lionheart share compensation in exchange for our beleaguered EMED shares. Even if they can somehow get away legally with wiping us out, I certainly hope they don’t, and wouldn’t even dream of it. Better karma to float us at least a lagniappe for our troubles.

TeacherMan, hope this info helps. Again, it's with the help of A.I. for your evaluation.

While your theories align with aggressive corporate restructuring tactics, the mechanism to achieve a zero-dilution outcome for existing Electromedical Technologies (EMED) common shareholders is incredibly narrow.

If Lionheart uses a manufactured default to strip EMED of its assets right before an IPO, it creates a massive litigation risk. Legacy noteholders and common shareholders can sue Lionheart for breach of fiduciary duty, fraudulent conveyance, and predatory lending. Institutional investors rarely touch IPOs with active or imminent shareholder litigation.

Evaluate the Two Restructuring Scenarios

Scenario A: The Loan Paid Off Noteholders (The Hidden Settlement Theory)

How it works: EMED used the cash proceeds from the $500,000 loan to quietly buy back, settle, or satisfy the $514,000 legacy convertible note obligation before it could convert into 3.1 billion shares.

The S-1 Impact: Clean and positive. Lionheart can file an S-1 showing a streamlined target acquisition with a known, fixed-dollar debt profile ($500k + interest/penalties) rather than a hyper-dilutive, toxic equity overhang.

The Missing Link: A cash settlement of debt must legally be disclosed under "Subsequent Events" or "Liquidity and Capital Resources" in public financial filings. If EMED's Q1 2026 report still reflects the $514,000 noteholder balance alongside the defaulted $500,000 loan, the overhang is not gone. A company cannot selectively hide the retirement of a major liability to mask a rollup, as doing so violates basic SEC financial reporting guidelines.


Scenario B: "Loan-to-Own" Asset Seizure (The Foreclosure Theory)

How it works: Lionheart intentionally structured the $500,000 loan with aggressive terms (20% interest for 4 months + immediate default penalties) and secured it with "all of the assets of the company." Because EMED defaulted on April 1, 2026, Lionheart now holds the legal right to foreclose on EMED's core IP, manufacturing tech, and inventory.

The S-1 Impact: Disastrous for public markets. If Lionheart seizes the assets and leaves EMED as an empty shell, they effectively wipe out the 3.1-billion-share note overhang—but they also wipe out your common shares. The "empty shell" EMED left behind would still hold the $514,000 debt, while Lionheart goes public with the clean operational assets.



Analyze How This Looks on a Form S-1

If Lionheart is preparing an independent IPO in 2026, the SEC requires rigorous disclosure regarding Related Party Transactions and asset acquisitions.

Transaction Method - Appearance on S-1 / Investor Perception

1. Legitimate Debt Refinancing: Highly Favorable. Standard corporate rollup behavior. It shows Lionheart acting as a financial backer to stabilize a target entity before bringing it public.

2. Strategic Loan Forgiveness: Favorable. If Lionheart converts the $500,000 loan into equity as part of the formal rollup agreement, public investors view it as a committed parent company reinforcing its subsidiary.

3. Asset Seizure via Default: Extremely Negative (Red Flag). If Lionheart uses a manufactured default to strip EMED of its assets right before an IPO, it creates a massive litigation risk. Legacy noteholders and common shareholders can sue Lionheart for breach of fiduciary duty, fraudulent conveyance, and predatory lending. Institutional investors rarely touch IPOs with active or imminent shareholder litigation



Action Plan to Protect and Verify Your Position

To determine if you are facing a massive dilution event or a complete asset wipeout, execute the following forensic steps:

1. Audit the Q1 2026 Balance Sheet: Open EMED’s 2026 Q1 report. Check the liabilities section specifically for the line item tracking "Convertible Notes Payable." If that $514,000 is still listed, the overhang remains active and dangerous.

2. Review the "Related Party" Disclosures: Look at who the "company" is behind the $500,000 loan. If it is officially unmasked as Lionheart or a Lionheart executive, strict regulatory rules bind their ability to arbitrarily seize assets without public disclosure.

3. Monitor Default Notices: Watch the OTC Markets disclosure stream for a "Notice of Foreclosure" or "UCC-1 Financing Statement" enforcement. If Lionheart moves to seize the assets under the security agreement, common equity value drops to near-zero immediately.

4. Evaluate the Rollup Agreement Terms: A legitimate rollup will dictate exactly what happens to EMED stock (e.g., a 1-for-X share swap into Lionheart equity).

If a formal merger agreement is filed, look for a clause detailing the "treatment of outstanding convertible debt."

Your next logical step is to cross-reference the total liability balance from the 2025 annual report against the newly issued 2026 Q1 report to verify if the $514,000 noteholder debt was actively reduced or if it is sitting parallel to the defaulted $500,000 loan.

This all makes sense, Win, and I thank you for it. My question would be twofold. Do you think it’s possible the 500k loan was made in order for EMED to pay off noteholders, rather than “to keep the lights on”? And that that overhang might now be gone? I ask because the numbers somewhat align: 514k in noteholder debt; a new 500k debt. Possibly Lionheart *will* in fact forgive that loan, and that it was a form of payment now that they can’t report yet because they’d have to reveal the fact of the rollup before they’re ready to? What do you think are the chances of that? I ask because if the loan wasn’t for that, but was in fact for them to stay afloat (not sure why they would have to, with no rent, and presumably manufacturing and distribution costs covered by Lionheart in the meantime), then there is still the thorny thicket of the $514k due to the noteholders, who could demand 3.1B shares to convert that note. Hoping beyond hope that that note overhang is gone, because it would preserve the power of our shares instead of diluting them by almost 100% (current OS 3.72B, potential note overhang 3.1B). What say you?

No worries. GLTA

Sorry, meant to reply to TeacherMan. Below is some information I was able to find with the help of AI. It’s been a long road and somehow, I did not realize just how long a roll-up and merger before Lionheart Health’s independent IPO would actually take. It’s obvious that Lionheart Health has done an amazing job preparing for the IPO and I have confidence that it will be very successful given Howard Leonhardt’s incredible vision, background, track record and experience. I’m still holding my shares and still believe that the real value will come from shares in Lionheart’s IPO, even at a lower share conversion ratio than maybe we expected. I can’t see taking a loss and selling at .0001 when there may be a chance for a much greater return in the long run. There is also a possibility that the stock price will pop once we get a PR or the S-1 is filed publicly. It all depends on your own individual trading strategy. JMHO.

Financial and Strategic Realities

The $500,000 loan was highly likely a bridging capital arrangement structured for discounted equity. In a pre-IPO consolidation or roll-up strategy, a primary partner (Lionheart Health) often extends short-term debt to a financially strained target (EMED) to keep operations afloat until the IPO triggers. It serves to keep the target company solvent while legal and valuation frameworks are being drawn up.

Since EMED defaulted, it creates a tactical pivot point. Rather than initiating hostile liquidation, a corporate default in a friendly pre-IPO rollup typically gives the lender more leverage.

Matthew Wolfson (CEO of EMED) may very well be navigating deliberate delays to leverage a better deal, but his hand is weak.

Leverage: EMED possesses the manufacturing infrastructure, established sales channels, and historical device distribution networks that Lionheart needs to scale immediately.

Vulnerability: EMED’s May 20, 2026, Q1 report showing poor financials and their status as an alternative reporting company (having filed Form 15 to suspend SEC reporting) signals that they are running out of runway.

Wolfson is likely trying to negotiate higher valuation metrics for EMED shareholders in the final S-1 roll-up equity split, but Lionheart holds the leverage because of the debt default.

Because Lionheart is targeting an IPO, Howard Leonhardt will want a clean, reputationally safe resolution. The most probable path includes:

The "Debt-for-Equity" Friendly Rollup: To avoid public legal disputes that look bad on a pre-IPO S-1 filing, Lionheart could agree to forgive the $500,000 default in exchange for absorbing EMED completely. In this scenario, EMED shareholders would likely receive shares in the private Lionheart entity (or a specific allocation during the IPO transition). However, due to EMED's weak financial position, the conversion ratio would significantly dilute EMED’s existing equity.


Manufacturing: The Mettler Electronics, Anaheim, CA, connection.

EMED and Lionheart are actively utilizing Mettler Electronics in Anaheim, CA to anchor the new device platform.
This allows Lionheart to market a “Made in California” device backed by Mettler’s decades of reliable medical manufacturing.

The Design Alignment: Leonhardt Ventures' internal goal documents explicitly state their intent to "Launch sales USA and worldwide on Mettler 240 platform via Lionheart Health non-dilution path." The device known as the Lionheart 240 Stimulus™ is heavily built upon or derived from the Mettler Electronics Sys*Stim 240 neuromuscular stimulator architecture. Mettler is a legacy manufacturer in Anaheim, CA with existing FDA 510(k) clearances, making them an ideal OEM partner to quickly scale stable hardware. Mettler Electronics frequently acts as an OEM (Original Equipment Manufacturer) for clinical electrotherapy hardware, supplying standard casings and boards that companies then customize.


The Lionheart 240 Stimulus™ consists of:

EMED Proprietary Components / iDNA tech
Mettler Outer Shell/Core Power Architecture – Integrates the numbers of Mettler’s FDA-cleared Sys*Stim 240 hardware to leverage pre-existing regulatory clearances.
Lionheart Bioelectric Signaling Protocols

The core value proposition of the Lionheart 240 Stimulus is the integration of EMED’s WellnessPro Infinity digital synthesis/iDNA technology alongside Lionheart’s patented software protocols for bioelectric protein expression.

The strategic partnership combines Lionheart's patented bioelectric signaling software with different physical hardware units. The various device name changes from EMED’s WellnessPro Infinity 240 to the current pictured Lionheart 240 Stimulus™ gradually distanced the device from the micro-cap EMED brand, positioning it under the Lionheart IPO – a clear transition from an EMED-owned asset to a Lionheart-controlled technology.


Why Two Similar Versions Exist on the Website

https://lionhearthealthstim.com/medspas-clinics-order/

On the Lionheart Health Stim portal, both the WellnessPro Infinity, Legacy EMED portable/pod platform ($14,995) and the Lionheart Stimulus 240, Mettler Electronics Sys*Stim platform ($6,195) appear because they target entirely different market segments and regulatory pathways.

They essentially do the same basic biological task—delivering electrical current to stimulate tissue. However, keeping both options live lets the company capture two distinct price points while maintaining cash flow from EMED’s existing pre-orders during the transition.


Product Branding & Manufacturing

Mettler Electronics & the 240: The Lionheart 240 Stimulus has distinct hardware that closely resembles the Mettler Sys*Stim 240 neuromuscular stimulator. Mettler Electronics frequently acts as an OEM (Original Equipment Manufacturer) for clinical electrotherapy hardware, supplying standard casings and boards that companies then customize.

Why Two Devices? The WellnessPro Infinity and Lionheart 240 Stimulus are both shown because they target different customer bases. The Infinity is historically positioned as a general-use or at-home unit, while the 240 Stimulus is tailored strictly for clinical aesthetics and longevity protocols (e.g., hair/skin regeneration) inside Lionheart MedSpas.

Medical Offices and the VA: The WellnessPro Infinity will likely continue to be marketed to medical offices and the VA, as it carries an FDA 510(k) clearance for pain management. Lionheart Health plans to program these legacy devices with their own patented bioelectric signaling protocols to broaden the treatment modalities.

EMED's Sales Team: EMED previously onboarded a medical group with hundreds of sales reps. However, as the roll-up progresses, these sales efforts are likely being folded into Lionheart's overarching 124-location international Longevity MedSpa expansion to push proprietary "membership" programs.

AI Summary of the Financial Report
🎯 Bottom line

The strongest positives are:

✔ Real operating company
✔ Real products
✔ Real revenue
✔ Improving loss trajectory
✔ Active restructuring
✔ Real Lionheart relationship
✔ Extremely low valuation asymmetry

I will revisit this portion of the financial updates as it is very important to what transpires here. More than likely the last time I post here (unless in response), as although I stated I wouldn't, I have unloaded all shares I held. I am done trading the putrid cess pool of the unbelievably corrupt Pink sheets. GLTA here. Hopefully a positive turn around coming, but would not count on it.

In December 2025, the Company entered into a loan and security agreement (“Loan”) with a company for the amount of $500,000
with a fixed interest payment and balloon payment due in full on April 1, 2026 (the “Maturity Date”). The loan has a fixed interest
payment of $100,000 due upon maturity. Interest expense totaled $86,538 for the three months ended March 31, 2026.
The Loan is fully secured by all of the assets of the Company. As the Loan was not paid by the Maturity Date, a $50,000 penalty has
also been assessed against the Company. See Note 12.
While the Company has purchase orders and pending deposits, it is seeking to collect to repay the Loan, there is no assurance if and
when it will do so and ultimately all of the assets could be subject to foreclosure and sale to repay the Loan.

What do you make of it, Win? It seems your conjecture was correct—they no longer lease a space.
Unchanged are the 3.1+B possible shares owed to creditors if they call for them (in connection to over 500k debt). That would bring the OS count to 7B+. That would of course require raising the AS count. Obviously we’re hoping they don’t do that. It would be wonderful if the AS number could stay capped at 5B—or even better, if the OS number could stay at the 3.732B number it’s at now.  
Do you see a scenario where, as part of buying EMED, Lionheart just pays off the creditors directly? And then buys the company out with another amount—hopefully $25M? That’s provided the creditors are willing to take payment and not shares. Sometimes these predatory lenders want the shares, because the profit margins are higher than if they just get paid off, since the shares are valued at way below market. They make a healthy profit even if they sell at .0001, in theory.
I’m sitting on a ton of shares and have held for quite some time, even though I could pay off my credit card bill in one shot if I dumped into the .0001 bid. I’m hoping (and reasonably expecting) that holding will yield a lot more than a(n admittedly large) credit card payment. The money, as the saying goes, is made not in the buying or selling, but in the waiting. Make no mistake, though: it’s been interminable.
Fervently wishing for this to go the right way for all of us!

https://www.otcmarkets.com/file/company/financial-report/565037/content

California Business Journal – May 19, 2026
Lionheart Health’s No. 1 Ranking Signals a Bigger Shift in Healthspan Innovation
https://calbizjournal.com/lionheart-healths-no-1-ranking-signals-a-bigger-shift-in-healthspan-innovation/?fbclid=IwY2xjawR5lK5leHRuA2FlbQIxMQBicmlkETFEUFgxbnBMc3lwYTJlYXVoc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHrKyy43_Neuzcf1bRWbozQaItVPmgrC_LuLJYTuedoaKFrKs9j6LvohT9_6-_aem_KMEMfzuN1UvmCITloD-7sA

The slide deck that was presented at the International Aging and Gerontology Conference that was worldwide by Zoom May 11-12. This event served as a major worldwide forum for researchers, clinicians, and policymakers, covering topics like geriatric care, neurodegenerative disorders, and social aging.
Lionheart Health - 2026 Clinical Progress Report

Timestamp 03:13 Lionheart 240 Stimulus TM



The distinct look of the Lionheart 240 Stimulus TM most likely reflects a transition from the general-purpose WellnessPro Infinity design to a specialized, clinical aesthetic tailored for Lionheart MedSpa locations. The Lionheart 240 Stimulus TM suggests significant branding and hardware shift as part of the planned roll-up.

https://www.otcmarkets.com/stock/EMED/profile

SINCE TODAY 🔥 " Pink Limited " 🤭🥱😡🤮🤮🤮🤢🥵 great work

Is punctuality (or proper submission, if one has known about it for a long time) his strength ?

he's always late

https://www.otcmarkets.com/file/company/financial-report/562923/content

WOLFSON +1 888-880-7888

ir@electromedtech.com
electromedtech.com

https://www.otcmarkets.com/stock/EMED/disclosure

Probably wont see Q1 financials until sometime in July. I would expect to see the bid flushed again prior to that. That is the Wolfson way.

I see you’re back, trying very hard to sow your seeds of doubt. “The sky is falling”!!! Is it possible? Yeah, but highly unlikely!! It’s more likely we will get a PR with the 2026 1st quarter report due shortly. If you’re such an astute investor, why haven’t you sold and moved on? Thanks, but I see value in holding.

Possible

Is that even possible? Or is something like that feasible? ...that you buy a company, work with it, extract the essentials, and leave behind only an empty shell. Just a shell with no business operations, where only the shareholders are trapped and can never escape, and the business and software have been extracted from the company (e.g., through a subsidiary where the software and business are placed after the purchase, leaving the main office empty-handed with its shareholders). ...is something like that even possible?

Where is that dedicated user who found something new every week? (It was never anything official or submitted news, but sometimes you could have thought EMED was serious.)

You're absolutely right, and I completely agree with you. It was definitely (one hundred percent) my mistake. I was stupid and a complete idiot for investing here. And is there a company that's even less transparent than EMED? Even $Bleg speaks to its shareholders and makes tweets, and it's unbelievable that I now find $Bleg more reputable than EMED, lol
all only imho

Personally, I would prefer it if people always told the truth honestly and concisely:

"You were ripped off, we were simply bought out. We were simply swallowed up, and shareholders see nothing (after the company is bought, all shareholders are left empty-handed), and the company is simply dissolved. I only needed you in the past period because of the dilution; after all, I wanted money."

Wouldn't this honesty be better than not answering emails or having no contact with shareholders? lol.

I much prefer this kind of honesty—in relationships, in business, and also in the stock market. Then everyone would know where they stand and could learn from it. And it's hard to admit mistakes, but my biggest mistake in the last 24 months was investing money here. Maybe you get lucky and end up with 0.0002, but that's not going to happen right now because you need a large volume to get to 0.0002, and volume only exists if there's good news. So this whole thing is completely hopeless. And soon it will be June, and 2025 was mentioned here. Soon + early 2026 was mentioned. Soon + then April was mentioned +. Now it's mid-May and soon June... So I'm looking for facts and the fact is: "We're at 0.0001 and I don't see any huge news or deal."


all only imho

it's your company, your problem. it's actually a PRIVATE company if you have less than 50 shareholders. as for due diligence it's the shareholders responsibility to do your own research and verify the financial statements of the company. not the gov't problem or the courts. and dont waste the courts time on insider trading violations etc. or any fraud complaints about company going bankrupt when it losing money

We shareholders are being ripped off.
imho

LOL , NOT 2026 🤣🤣🤣🤣

2025 ? LOL

WHEN ? 2030 ?

of course

Notice how the ask keeps getting stacked by 20M or so shares. I believe that is Wolfson and his kronies at work. I truly believe the OS count is much higher than what is showing and this clown Wolfson is hiding the true OS count.

Come on wolf 
Top 10 
Feed your shareholders!!!!

Like i said. Lionheart will buy it for cheap and we're going to be screwed 

I would not be surprised if LionHeart Health was the lender listed in the statement fron the Annual report listed below. Wolfson is absolutely clueless on how to run a legitimate business. If this is the case, cant blame LionHeart from taking advantage of his incompetence.

I"n December 2025, the Company entered into a loan and security agreement (“Loan”) with a company for the amount of $500,000
with a fixed interest payment and balloon payment due in full on April 1, 2026 (the “Maturity Date”). The loan has a fixed interest
payment of $100,000 due upon maturity.
The Loan is fully secured by all of the assets of the Company. As the Loan was not paid by the Maturity Date, a $50,000 penalty has
also been assessed against the Company.
While the Company has purchase orders and pending deposits it is seeking to collect to repay the Loan, there is no assurance if and
when it will do so and ultimately all of the assets could be subject to foreclosure and sale to repay the Loan. "

Lionheart Health just submitted their application to move from the top 40 semi finals to the top 10 finals of the X Prize healthspan $101 million dollar competition. It puts them in a position to receive a one million dollar prize in early June and qualifies them for the $81M grand prize about 18 months after that. Good luck to the entire team!!

Looks like more folks may have unloaded their bags at trip 1 today. I know just as soon as I did, Wolfson would come out with a nice little nugget of a PR. The positive here is that Wolfson is keeping the company current so there is always a chance for a pop. Not selling my shares at trip 1

There's no point. Everything is based on a rumor. If it's not signed, it's not official

To me, there is no doubt that EMED will be merging with Lionheart Health in a roll-up acquisition very soon after an admittedly long wait without information from EMED except for what has been gleaned from Lionheart Health and other sources, hence the share price. I fully realize that the share price is not likely to rise until a PR is released and am simply sharing any information while doing my own due diligence. However, I will call it out when it appears that concrete facts are being intentionally distorted or misrepresented to serve an agenda. The process of merging a few companies into Lionheart Health for a 2026 IPO involves complex private negotiations. NDA’s are standard to prevent leaking sensitive deal terms before they are finalized. SEC regulations strictly prohibit “gun-jumping”, which is making public statements that could be seen as “conditioning the market” for an upcoming IPO. As Lionheart Health prepares for its independent IPO, any promotional PR from a major rollup component like EMED could be viewed as an illegal attempt to hype the offering. To stay within legal “safe harbors” (like Rule 163A), companies often choose total silence rather than risking a statement that mentions the IPO or future prospect. imho

I see a news item from 2023 and then another from June 2025 = I think what's important are "officially confirmed and submitted" news items, and these are "unfortunately" rare. Add to that Dilu, and we're already at 0.0001.

https://www.otcmarkets.com/stock/EMED/news


// No one questions their information they've found; 👌
everyone admires their fantastic work. 👍
Everyone is amazed by their search for hidden information, 💪

but

ultimately, we need something official

and for almost a year, there's been nothing official from the company, and most people don't like that

And that's why the PPS isn't rising.

When something official comes out, like with $ecox, that stock rises sharply from 0.0002 (also with a drastically inflated structure),

but here at $EMED, there's nothing official, and the CEO's communication with shareholders and the public is terrible. If he simply kept us updated monthly via tweets or shareholder letters, the PPS would be in a completely different position.

Maybe like $ecox (0.0017), but if you don't provide any information for almost a year, it's logical that the price ends up at 0.0001 with no bid.
imho